No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 27
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for LeonaBio, Inc. (LONA) stock was $5.75 as of Oct 6, 2026, 4:00 PM EDT, up 3.05% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +34.6% · 3-year avg -32.3%/yr · 5-year avg -43.1%/yr
LeonaBio, Inc. operates as a biopharmaceutical firm engaged in clinical-stage development.
Biotechnology · Bothell, WA
Next Earnings Date
Nov 5, 2026
30 days away
EPS Estimate
-0.69
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.80
vs Estimate
$-1.36
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1LONA | $22.68M | $5.75 | +3.05% | +34.59% | -43.13% | N/A | N/A |
| 2RNTX | $23.06M | $0.82 | +0.00% | -30.55% | N/A | N/A | vs LONA |
| 3MODD | $22.25M | $2.73 | +18.70% | -88.60% | N/A | N/A | vs LONA |
| 4AYTU | $22.00M | $2.05 | +0.49% | -6.80% | -48.14% | -68.87% | vs LONA |
| 5TXMD | $23.38M | $2.02 | +0.50% | +87.29% | -44.16% | -40.05% | vs LONA |
| 6KYNB | $24.13M | $5.96 | -2.13% | -47.92% | -52.67% | -35.88% | vs LONA |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 3 analysts
Average Price Target
$17.33
+201.4% upside
Low
$15.00
Current
$5.75
High
$20.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.69 | $-0.69 | $-0.69 | 2 |
| Quarter ending Dec 2026 | $-0.60 | $-0.60 | $-0.60 | 2 |
| Quarter ending Mar 2027 | $-0.76 | $-0.76 | $-0.76 | 1 |
| Quarter ending Jun 2027 | $-0.79 | $-0.79 | $-0.79 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-3.39 | $-2.83 | $-2.08 | 3 |
| FY 2027 | $-2.90 | $-2.34 | $-1.77 | 3 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $0.00 | $0.00 | $0.00 | 0 |
| FY 2027 | $0.00 | $0.00 | $0.00 | 0 |
